摘要
目的评价CYP2D6*10(c.100C>T)及ADRB1(c.1165G>C)不同基因型分组的患者在服用β受体阻滞剂类降压药时的治疗效果是否具有显著性差异。方法通过收集300例美托洛尔用药患者病历资料及全血样本,进行CYP2D6*10及ADRB1(c.1165G>C)基因检测分型,根据基因型将患者分为预期疗效一般(+)组、预期疗效较好(++)组及预期疗效显著(+++)组,研究这300例服用美托洛尔类药物的患者降压效果在不同基因型分组间的统计学差异。结果300例高血压患者的CYP2D6*10及ADRB1(c.1165G>C)突变型等位基因频率分别为41.2%及34.3%,评估预期疗效显著人数88例。使用美托洛尔后收缩压下降水平(△SBP)+组与++、+++组相比较P<0.05,差异具有统计学意义,舒张压下降水平(△DBP)+、++、+++组两两相比较,差异均有统计学意义(P<0.05)。结论ADRB1(1165G>C)与CYP2D6*10不同基因型患者服用美托洛尔后降压治疗效果不同,可为临床β受体阻滞剂类降压药的精准用药提供指导及依据。
Objective To assess the significant differences in the therapeutic effects ofβ-blocker antihypertensive drugs on hypertension patients with genotypes of CYP2D6*10(c.100C>T)or ADRB1(c.1165G>C).Methods Medical records of 300 hypertension patients taking metoprolol were collected,and their whole blood samples were subjected to gene detection of CYP2D6*10 and ADRB1(c.1165G>C).According to the therapeutic efficacy,hypertension patients with the genotype of CYP2D6*10 or ADRB1(c.1165G>C)were divided into fair expected efficacy group(+),good expected efficacy group(++)and excellent expected efficacy group(+++).The significant differences in the antihypertensive effect of metoprolol influenced by the genotypes of CYP2D6*10 and ADRB1(c.1165G>C)were analyzed.Results The frequencies of CYP2D6*10 and ADRB1(c.1165G>C)mutant alleles in 300 hypertension patients were 41.2%and 34.3%,respectively.A total of 88/300 hypertension patients had excellent expected efficacy.There were significant differences in the reductions of systolic blood pressure(ΔSBP)and diastolic blood pressure drop(ΔDBP)after metoprolol medication between+group,and those of++,and+++group(both P<0.05).Conclusion Patients with different genotypes of adrb1(1165g>C)and CYP2D6*10 have different antihypertensive effects after taking metoprolol,which can be used to provide guidance and references for the accurate medications ofβ-blocker antihypertensive drugs.
作者
赵佳
沈婷
张鑫
刘伟
宗寿洋
ZHAO Jia;SHEN Ting;ZHANG Xin;LIU Wei;ZONG Shouxiang(Department of Clinical Laboratory,Xi'an Central Hospital,Xian,Shaanxi 710003,China;Department of Clinical Laboratory,Jinhu People's Hospital,Jinhu,Jiangsu 211600,China)
出处
《国际检验医学杂志》
CAS
2021年第S02期48-51,共4页
International Journal of Laboratory Medicine
基金
西安市科技计划项目(201805102YX10SF36(6))
西安市中心医院科研基金(2021YB04)。
